Cyclooxygenase-2 and synthesis of PGE2 in human bronchial smooth-muscle cells

Am J Respir Crit Care Med. 1997 Mar;155(3):864-8. doi: 10.1164/ajrccm.155.3.9117018.

Abstract

The purpose of this study was to determine the mechanism of enhanced prostaglandin synthesis in cultured human bronchial smooth-muscle cells challenged with interleukin-1 beta (IL-1 beta). Cells were incubated with IL-1 beta (10 to 50 U/ml) for 0 to 24 h. Prostaglandin E2 (PGE2) production was evaluated through the conversion of exogenous (14C)-arachidonic acid and specific enzyme immunoassay of endogenous products. IL-1 beta enhanced PGE2 formation in a concentration- and time-dependent manner, reaching its peak at 6 to 8 h and fading at 18 to 24 h. Immunoblot analysis showed that the inducible cyclooxygenase enzyme (COX-2) was expressed only in IL-1 beta treated cells, whereas the constitutive isoform of cyclooxygenase (COX-1) remained unaltered. COX-2 expression and PGE2 formation were inhibited by dexamethasone (2 microM), cycloheximide (10 microM), and IL-1-receptor antagonist (IL-1 ra) (250 ng/ml), independently. PGE2 synthesis was significantly reduced by compound SC-58125, a specific COX-2 inhibitor. The close parallelism between the kinetics of COX-2 protein expression and PGE2 accumulation, as well as the constitutive nature of COX-1 isoform, indicate that IL-1 beta-driven PGE2 formation in human bronchial smooth-muscle cells is mediated by de novo expression of COX-2 enzyme.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Arachidonic Acid / pharmacology
  • Blotting, Western
  • Bronchi / cytology
  • Bronchi / metabolism*
  • Cells, Cultured
  • Cycloheximide / pharmacology
  • Cyclooxygenase 1
  • Cyclooxygenase 2
  • Cyclooxygenase 2 Inhibitors
  • Cyclooxygenase Inhibitors / pharmacology
  • Dexamethasone / pharmacology
  • Dinoprostone / biosynthesis*
  • Dose-Response Relationship, Drug
  • Humans
  • Immunoblotting
  • Interleukin 1 Receptor Antagonist Protein
  • Interleukin-1 / pharmacology
  • Isoenzymes / biosynthesis*
  • Membrane Proteins
  • Muscle, Smooth / drug effects
  • Muscle, Smooth / metabolism*
  • Peroxidases / metabolism*
  • Prostaglandin-Endoperoxide Synthases / biosynthesis*
  • Pyrazoles / pharmacology
  • Receptors, Interleukin-1 / antagonists & inhibitors
  • Sialoglycoproteins / pharmacology

Substances

  • Cyclooxygenase 2 Inhibitors
  • Cyclooxygenase Inhibitors
  • IL1RN protein, human
  • Interleukin 1 Receptor Antagonist Protein
  • Interleukin-1
  • Isoenzymes
  • Membrane Proteins
  • Pyrazoles
  • Receptors, Interleukin-1
  • Sialoglycoproteins
  • 1-((4-methylsulfonyl)phenyl)-3-trifluoromethyl-5-(4-fluorophenyl)pyrazole
  • Arachidonic Acid
  • Dexamethasone
  • Cycloheximide
  • Peroxidases
  • Cyclooxygenase 1
  • Cyclooxygenase 2
  • PTGS1 protein, human
  • PTGS2 protein, human
  • Prostaglandin-Endoperoxide Synthases
  • Dinoprostone